EXHIBIT 10.2                           
 
                           AMENDED AND RESTATED
                            GLYBURIDE AGREEMENT


          THIS AMENDED AND RESTATED GLYBURIDE AGREEMENT (the "Agreement"), 
effective this 1st day of January, 1997 (the "Effective Date"), is by and 
between HOECHST MARION ROUSSEL, INC., a Delaware corporation ("HMRI"), and 
COPLEY PHARMACEUTICAL, INC., a Delaware corporation ("COPLEY").

W I T N E S S E T H:

          WHEREAS, HMRI is engaged in the manufacture, for the United States 
of America market, of non-micronized glyburide in finished dosage forms (the 
"Product" or "Products") pursuant to New Drug Application #17-532 (the "NDA"), 
and

          WHEREAS, COPLEY desires to purchase and market the Products, under 
its own name and under the private label name of certain of COPLEY's customers 
in the Territory (as hereinafter defined), and

          WHEREAS, HMRI desires to supply Product to COPLEY, upon the terms 
and conditions provided herein.

          WHEREAS, COPLEY and HMRI are parties to that certain Glyburide 
Agreement dated as of February 14, 1994 (the "Glyburide Agreement") and the 
parties wish to amend and restate the Glyburide Agreement to include certain 
new agreements between HMRI and COPLEY.

          NOW THEREFORE, the parties hereto agree as follows:

1.   MANUFACTURE, PURCHASE AND SALE OF PRODUCT, AND HMRI REVENUE SHARE

   1.1  Purchase and Sale.  Pursuant to the terms and conditions of this
Agreement consistent with 21 CFR 314.70(d)(4), HMRI agrees to manufacture 
exclusively for COPLEY, during the Term (as defined in Section 11.1 hereof) of 
this Agreement, generic versions of the 1.25 mg, 2.5 mg and 5.0 mg strengths 
of HMRI's standard DiaBeta(R) (glyburide) formulation, for sale by COPLEY to 
the trade in the Territory under the COPLEY label and the private label of 
certain of COPLEY's customers.  For the Term, and thereafter in the event of 
renewal or extension (as set forth in Section 11 hereof), COPLEY agrees to 
purchase all of its requirements for the Product for sale in the Territory 
from HMRI and HMRI agrees to supply all of COPLEY's requirements for the 
Product.  It is understood by the parties that the Product is produced in 
campaigns of a minimum quantity set forth in Schedule 1.1 of this Agreement 
(the "Minimum Quantity").  Regardless of COPLEY's requirements under this 
Section 1.1, COPLEY hereby agrees to place firm and binding orders for, and 
to purchase and take delivery from HMRI of, quantities of the Product and any
multiples thereof to be delivered to COPLEY in each calender month during the
Term of this Agreement that are not less than the Minimum Quantity.  The 
parties acknowledge that shipments of the Product by HMRI may vary from the 
Minimum Quantity by up to ten percent more or less than the Minimum Quantity.

<PAGE 2> 

  1.2  Product Specifications and Manufacturing Technology Transfer Option.  
HMRI will manufacture the Product for COPLEY in oblong, scored tablets in 
strengths and colors as follows:

                 Strength:                       COPLEY Generic
                 --------                        --------------

                  5.0 mg                             blue
                  2.5 mg                             light pink
                  1.25 mg                            white

         The Product shall meet the specifications set forth in the NDA, as 
such specifications may be changed from time to time.  HMRI shall on a timely 
basis advise COPLEY of any changes made with respect to the NDA.

   1.3  Labeling and Packaging.  Packaging and labeling for the Product shall 
be consistent with the U.S. Food and Drug Administration (the "FDA") approved 
labeling for the Products, and shall be in dosage strengths and colors as set 
forth in Section 1.2 herein and in packaging configurations as subsequently 
mutually agreed upon by the parties.

   1.4  Rolling Forecasts and Orders.  On a monthly basis COPLEY will provide 
HMRI with 12-month rolling forecasts by package size (SKU) and by distributor.  
The first rolling forecast will be due upon execution of this Agreement.

         COPLEY will be obligated to place orders and purchase from HMRI the 
following:

      a.  100% of the amounts forecast for the first three months of each    
           rolling forecast; and

      b.  50% of the amounts forecast for months four, five and six of each  
           rolling forecast.

         Each purchase order shall contain a shipment date in accordance with 
HMRI's manufacturing lead time of twelve (12) weeks, and be subject to the 
provisions of Section 9 hereof.  COPLEY will supply HMRI with monthly sales 
summaries by class of trade at HMRI's request.

   1.5  Cost of Goods and Payment.  Annually in January of each calendar year 
during the Term of this Agreement, HMRI shall provide to COPLEY cost of goods 
pricing for the Products during that calendar year.  HMRI cost of goods 
pricing provided to COPLEY for each calendar year subsequent to the initial 
pricing provided in Exhibit A of this Agreement shall be accompanied by such 
reasonable detail and documentation as to enable COPLEY to understand the 
basis for such pricing.  The pricing shall include material costs (including, 
but not limited to, bulk active ingredient costs which bulk active costs shall 
include a reasonable profit margin to HMRI to be negotiated based upon quotes 
from qualified, bona fide sources), manufacturing charges and packaging costs 
on a fully allocated basis according to generally accepted accounting 
principles.  HMRI's cost of goods pricing to COPLEY during 1997 for packaged 
finished goods FOB Bridgewater, New Jersey shall be as set forth in Exhibit A, 
attached hereto and made a part hereof.  Notwithstanding the foregoing 

<PAGE 3>

sentence, the parties understand that HMRI may move its production site of any 
Product to a different site and that in such event Exhibit A of this Agreement 
will be amended to reflect HMRI's cost of goods pricing to COPLEY at such new 
production site.  COPLEY agrees to pay the invoice amount for the Products 
ordered by COPLEY.  Terms of payment shall be open account, net forty-five 
(45) days from the later of receipt of invoice or shipment of the Product.

   1.6  Advertising/Marketing/Sales Costs and Product Pricing.  COPLEY shall 
be responsible for all advertising, marketing and sales costs associated with 
Product distribution.  COPLEY will have complete authority for all pricing 
decisions for the Product sold by COPLEY.  COPLEY agrees to keep HMRI 
reasonably informed of price changes in excess of twenty-five percent (25%) or 
such other percentage as mutually agreed to by the parties.

   1.7  HMRI Net Profit Margin Share.  The parties agree that HMRI shall 
receive, on a monthly basis, payments from COPLEY which shall be equal to 
[*] of the COPLEY Net Profit Margin realized on sales of any Product in the 
Territory during each preceding calendar month.  For the purposes of this 
Section 1.7, COPLEY Net Profit Margin shall mean COPLEY Product gross sales 
less actual chargebacks, rebates, price adjustments, returns and cash 
discounts and less cost of goods as set forth in Section 1.5 herein.  Exhibit 
B, attached hereto and made a part hereof, sets forth the method of 
calculation of HMRI Net Profit Margin Share.  The monthly payments 
contemplated by this Section 1.7 shall be made by check delivered to HMRI not 
later than ninety (90) days following the close of each calendar month during 
the Term of this Agreement.

2.  TERRITORY

    This Agreement encompasses only the United States of America and its 
possessions and territories including Puerto Rico (the "Territory") and gives 
COPLEY the right to market to all classes of trade in the Territory.

3. 	REGULATORY MATTERS

    3.1  FDA Approval.  HMRI represents and warrants that the Product is 
approved by the FDA for the uses set forth in HMRI's labeling.  COPLEY and 
HMRI agree to take all necessary action to obtain and maintain any approvals 
necessary to permit COPLEY to sell the Product under its own name in the 
Territory in compliance with applicable federal and state drug laws.  HMRI and 
COPLEY agree to coordinate with each other concerning all changes to Product 
labeling.

    3.2  Regulatory Correspondence.  COPLEY and HMRI shall make available to 
each other, within three (3) days of receipt, regulatory correspondence 
covering the following issues:  regulatory letters, Product recalls, 
withdrawal of Product, and correspondence bearing on the safety and efficacy 
of the Product.

	

[*] Confidential portion has been omitted pursuant to a request for 
confidential treatment and has been filed separately with the Commission.


<PAGE 4>

   3.3  Product Inquiries and Complaints/Recalls.  COPLEY will promptly submit 
to HMRI all Product safety and efficacy inquiries, Product quality complaints 
and adverse drug event (ADE) reports received by it, together with all 
available evidence and other information relating thereto.  Except as 
otherwise required by law or governmental regulation, HMRI will be responsible
for investigating and responding to all such inquiries, complaints and adverse 
events regarding the Product.  It shall be the exclusive responsibility of 
HMRI to comply with all federal, state and local governmental reporting 
requirements regarding ADEs and Product quality matters, except where such 
events or matters are caused solely by acts or omissions of COPLEY, in which 
case HMRI may, consistent with applicable law and regulation, request COPLEY's 
assistance in such compliance.  HMRI will forward a copy of all FDA 
submissions concerning Product ADEs or any Product safety-related topic to 
COPLEY within ten (10) working days of submission.  In the event of a dispute 
in respect of the therapeutic action or quality of the Product:  (i) if the 
dispute involves only COPLEY and a subsequent purchaser then COPLEY and HMRI 
shall consult prior to any compromise or settlement of such dispute; and 
(ii) if the dispute involves COPLEY, HMRI and a subsequent purchaser then both 
parties must consent prior to any compromise or settlement of such dispute.  
COPLEY shall be responsible for forwarding recall materials received from HMRI 
designed to recover Products distributed by it and its private label customers 
in the event of a recall.  Expenses associated with a recall are to be borne 
by the party at fault.

   3.4  Quality Assurance.  In order to facilitate quality assurance 
activities with respect to the Product, HMRI agrees to (a) allow COPLEY at 
least once per year at mutually agreeable times to inspect/audit HMRI's 
facilities and records pertaining to manufacture, testing, storage and packaging
for compliance with Good Manufacturing Practice, 21 CFR 211, and (b) 
supply to COPLEY the results of all stability testing for the Product.  COPLEY 
agrees to allow HMRI at least once per year at mutually agreeable times to 
inspect/audit COPLEY's facilities and records pertaining to storage and 
distribution for compliance with Good Manufacturing Practice, 21 CFR 211.

   3.5  Additional Information.  COPLEY shall provide to HMRI in a timely 
manner, but in no event less than thirty (30) days prior to the due date of 
HMRI's annual report to the FDA with respect to the Product, all information 
which HMRI requests regarding the Product in order to comply with applicable 
federal and state drug laws.  Such information shall include, without 
limitation, quantities of the Product sold.  COPLEY shall be responsible for 
assuring that all promotional material produced by it relating to the Product 
comply with federal, state and local law.  COPLEY shall provide to HMRI prior 
to first use copies of all advertising, promotional material, labeling and 
other literature used on, or in connection with, the Product.  HMRI shall 
supply to COPLEY on a timely basis a copy of said FDA annual report.

4.	PROPRIETARY RIGHTS AND TRADEMARKS

    HMRI retains ownership of the NDA and any supplements thereto.  HMRI is 
the owner of certain proprietary information (the "Proprietary Rights") used 
in connection with the manufacturing, sale and distribution of non-micronized 
glyburide pharmaceutical preparations.  No such Proprietary Rights are being 


<PAGE 5>

assigned, licensed or otherwise transferred hereunder, and COPLEY acknowledges 
that it shall have no rights hereunder to any such Proprietary Rights and 
hereby agrees that it shall not contest or dispute the validity of or title to 
any of such Proprietary Rights.  Without limiting the generality of the 
foregoing, COPLEY agrees it shall not take or cooperate in litigation or 
threatened litigation which might or is intended to impair or attack such 
Proprietary Rights or which questions the paramount interest of HMRI or its 
affiliates, licensees or assignees in the same.  COPLEY and its private label 
customers shall market the Product under their own trade names and trademarks, 
which shall not be confusingly similar to the trademark of HMRI for its non-
micronized glyburide product.

5.  	SECRECY

    Except for literature and information intended for disclosure to 
customers, each party will treat as confidential all technical and commercial 
information acquired by it from the other party under this Agreement and will 
take all necessary precautions to assure the secrecy of such confidential 
information.  Each party agrees to return to the other party upon the 
expiration or termination of this Agreement all confidential technical and 
commercial literature, data, and information acquired from the other party.  
Neither party shall, during the term of this Agreement or for ten (10) years 
thereafter, without the express prior written consent of the other party, use 
or disclose any such information received by it from the other party pursuant 
to the transactions contemplated by this Agreement for any purpose whatsoever.

6.  	WARRANTY

    HMRI warrants that the Product manufactured by HMRI and sold to COPLEY 
pursuant to this Agreement will meet the specifications for Products set forth 
in the NDA in effect at the time of such shipment.  HMRI reserves the right to 
amend such specifications from time to time at the sole discretion of HMRI; 
provided that COPLEY is provided with written notice within a commercially 
reasonable period of time in advance in order to effect any necessary 
marketing or other changes and, provided further that such changes do not 
cause the Product delivered to COPLEY to cease to be the equivalent of the 
DiaBeta(R) then sold by HMRI.  All Products will conform to, and the Products 
manufactured by HMRI will be manufactured in conformity with, the regulations 
of the Federal Food and Drug Administration and any comparable state agency 
applicable thereto.  None of the Products contained in any shipment made 
hereunder to COPLEY will, at the time of delivery, be adulterated or 
misbranded within the meaning of the Federal Food, Drug and Cosmetic Act, as 
amended (the "Act"), and those applicable state laws substantially similar to 
the Act, as such Act and laws exist at the time of delivery.  None of the 
Products will be an article that may not, under the provisions of the Act, be 
introduced into interstate commerce.  The Products shall conform with any 
specifications and quality assurance requirements mutually agreed to in 
writing by the parties and, in any event, shall not contain any poisonous or 
deleterious material.  No Product shall infringe the patent, trade secret or 
other proprietary right of any third party.  THIS WARRANTY IS THE ONLY 
WARRANTY, EXPRESS OR IMPLIED, MADE BY HMRI AS TO THE PRODUCT, AND ALL OTHER 
WARRANTIES, INCLUDING MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, 

<PAGE 6>

ARE DISCLAIMED.  Except as otherwise provided in this Agreement, the exclusive 
remedy for breach of warranty shall be prompt replacement of the nonconforming 
Product at HMRI's expense with a like amount of the Product conforming to the 
above-stated warranty.  For purposes hereof, replacement may include 
reprocessing of the Product if done in a period of time commercially 
reasonable to COPLEY.  In no event shall HMRI be liable to COPLEY for any 
alteration, change, improper packaging or other improper treatment of the 
Product by COPLEY other than in accordance with HMRI's instructions; nor shall 
HMRI be liable to COPLEY for any damage arising solely from COPLEY's 
marketing, advertising, distribution or sale of the Product that conforms to 
the warranty set forth above.

7.  	COPLEY'S OBLIGATIONS

    COPLEY shall not alter the Product and shall not recommend or knowingly 
sell the Product for any uses except as described in the FDA approved Product 
labeling.

8.  	INDEMNITY

    8.1  Indemnification by HMRI.  HMRI shall defend, indemnify and hold 
harmless COPLEY and its affiliates (and each of their employees, officers, 
directors and stockholders) from and against any and all claims, liabilities, 
assessed damages, costs and expenses (including, without limitation, costs and 
expenses of investigation and settlement, court costs and attorneys' fees and 
expenses regardless of outcome, but excluding any indirect, incidental or 
consequential damages or losses and lost profits) arising out of any claim of 
defect in materials or workmanship of the Product, failure of the Product to 
conform to the express warranty set forth in Section 6 hereinabove or alleged 
or actual personal injury, illness, death or other harm, except to the extent 
such claim arises out of COPLEY's breach of this Agreement, negligence or 
misconduct.

   8.2  Indemnification by COPLEY.  COPLEY shall defend, indemnify and hold 
harmless HMRI and its affiliates (and each of their employees, officers, 
directors and stockholders) from and against any and all claims, liabilities, 
assessed damages, costs and expenses (including, without limitation, costs and 
expenses of investigation and settlement, court costs and attorneys' fees and 
expenses regardless of outcome, but excluding any indirect, incidental or 
consequential damages or losses and lost profits) to the extent caused by 
COPLEY's packaging, marketing, advertising, distribution or sale of Product 
that conforms to the express warranty set forth in Section 6 hereinabove or 
caused by alterations to the Product made by COPLEY after delivery by HMRI 
other than in accordance with the written directions of HMRI, except to the 
extent such claim arises out of HMRI's breach of this Agreement, negligence or 
misconduct.

   8.3  Indemnification Procedures.  The parties shall cooperate and give each 
other prompt notice of claims as to which indemnification may be claimed 
hereunder.  The indemnifying party may, at its option, control the defense of 
claims for which indemnification may be sought.  The indemnifying party shall 
not be required to indemnify the indemnified party for any claim settled 
without the indemnifying party's written consent.



<PAGE 7>


9.  ORDERS

   9.1  Placement of Orders.  All orders placed by COPLEY with HMRI hereunder 
shall be sent to the following address, unless otherwise notified in writing:

Hoechst Marion Roussel, Inc.
2110 East Galbraith Road
P.O. Box 156300
Cincinnati, OH  45215-6800
Attn:  Ronald R. Schallick
Telephone:  (513) 948-7197
Telecopy:  (513) 948-4547

   9.2  Shipment.  HMRI shall make every reasonable effort to fill COPLEY's 
accepted orders in accordance with COPLEY's requested delivery dates.  All 
shipments of the Product to COPLEY shall be accompanied by a certificate of 
analysis for each batch in said shipment, certifying that each batch was made 
in accordance with current Good Manufacturing Practices and the NDA and 
listing test results.  Deliveries to COPLEY shall be FOB, HMRI Bridgewater, 
New Jersey or such other U.S. location to which HMRI may move production of 
the Product.  COPLEY shall pay all shipping costs, including insurance.

   9.3  Risk of Loss.  Risk of loss shall pass to COPLEY upon shipment by 
HMRI.

   9.4  Claims.  COPLEY shall cause a commercially reasonable visual 
inspection of all shipments of the Product promptly after arrival if shipped 
directly to COPLEY, and shall give prompt oral notice of potential 
nonconforming goods, and within thirty (30) days after arrival of any such 
shipment, give written notice to HMRI of any claim that any Product included 
in shipment may not conform to any applicable specifications or warranty.  If 
shipment of the Product is to a destination other than COPLEY, any claims of 
non-conformity under this Section 9.4 must be made by COPLEY within ninety 90
days of actual delivery of the Product to such destination.  HMRI shall 
promptly replace such nonconforming Product with conforming Product at no 
additional cost to COPLEY.  COPLEY's failure to detect and/or give notice of 
any defect not readily identifiable upon commercially reasonable visual 
inspection shall not vitiate HMRI's obligations under the warranty and 
indemnification provisions of this Agreement.

10.  FORCE MAJEURE

    Neither party shall be responsible or liable, in any way, for any default 
in performance of this Agreement arising, directly or indirectly, from any 
cause beyond such party's control, including, without limiting the generality 
of this provision, fire, flood, tornado, cyclone, war, enemy action, embargo, 
strike, lockout, labor trouble, transportation difficulties, governmental 
order, proclamation or regulation, inability to obtain raw materials, fuel, 
power, packaging or other supplies, accident, explosion, riot, insurrection or 
expropriation of the plants by governmental authority, or failure to make 
delivery of the Product if the same shall be prevented or delayed by state or 
other governmental authority or as a result of requisitioning for allocation 

<PAGE 8>

to others by any governmental authority.

11.	TERM, TERMINATION AND BREACH

   11.1  Term.  The Term of this Agreement shall commence on the date first 
written above (the "Effective Date") and shall be in full force and effect 
until five (5) years from the Effective Date (such period being the "Initial 
Term") unless earlier terminated pursuant to Section 11.3 or 11.4 
(Termination).  This Agreement shall renew for subsequent five (5) year 
periods following expiration of the Initial Term (each an "Additional Term"), 
under the same terms and conditions as the Initial Term, unless terminated by 
written notice by either party not later than three (3) years prior to the 
termination of any Initial Term or Additional Term hereunder.


    The period of time between the commencement and the termination of this 
Agreement at the end of the Initial Term or the last Additional Term, if any, 
is referred to herein as the "Term."

   11.2  Renegotiation.  If either party gives notice of termination pursuant 
to Section 11.1  or if HMRI gives notice of termination pursuant to Section 
11.3(ii) or Section 11.4, the parties shall, for a period of three months 
following such notice, negotiate in good faith the terms and conditions under 
which the Agreement could be renewed or continued, as the case may be.

         (i)  In the event that HMRI provides notice to terminate pursuant to 
      this Section 11.1 or Section 11.4 and such renewal or continuation 
      negotiations are unsuccessful, this Agreement shall be terminated as of 
      the end of such three month negotiation period.  At COPLEY's written 
      request, HMRI shall provide COPLEY or its designee with such technical 
      assistance services reasonably necessary to enable COPLEY to manufacture 
      or have manufactured its own product versions of the Products pursuant 
      to Abbreviated New Drug Applications of COPLEY (the "COPLEY Products") 
      in the Territory; provided, however, that COPLEY shall have no right to 
      (a) require HMRI to transfer to COPLEY or any third party any right 
      whatsoever with respect to the NDA or the Proprietary Rights,  (b)
      require HMRI to provide technical assistance services to any third 
      party, or (c) transfer to any third party technical assistance services 
      learned under this Agreement.  In consideration of these technical 
      assistance services, HMRI shall receive a royalty of 20% of the COPLEY 
      Net Profit Margin (as defined in Section 1.7 herein) with respect to 
      sales by COPLEY of any COPLEY Product for a period of ten (10) years 
      from the date of first commercial sale of such COPLEY Product.

         (ii)  In the event that COPLEY provides notice to terminate pursuant 
      to this Section 11.1 and renewal negotiations are unsuccessful, HMRI 
      shall have no obligation to provide COPLEY with any technical assistance 
      services pursuant to this Agreement.

   11.3  Termination.

         (i)  Either party shall have the right to terminate this Agreement at 

<PAGE 9>

      any time by giving due notice to terminate this Agreement in any of the 
      following events:

           (a)  Insolvency or bankruptcy of the other party or the inability 
         or failure of the other party to perform any financial obligations as 
         the same become due;

           (b)  Failure of the other party to make required payment under this 
         Agreement where such failure continues after ten (10) days' notice 
         from the other party;

           (c)  Demonstrable inability of the other party to perform its 
         material obligations under this Agreement; and/or

           (d)  The enactment of any law, order or regulation by a   
         governmental unit that would impair or restrict the right of or the 
         ability of either party to terminate or elect not to renew this    
         Agreement or which would render it impracticable or impossible for     
         the other party to perform its obligations hereunder.

         (ii)  Either party shall have the right to terminate this Agreement 
         at any time upon six months' prior written notice if the COPLEY Net 
         Profit Margin as defined in Section 1.7 has been negative for six   
         consecutive months.

   11.4  HMRI Termination.  This Agreement may be terminated at any time by 
HMRI upon written notice to COPLEY that the bulk active ingredient cost 
component of material costs under Section 1.5 herein is less than HMRI's 
actual cost per U.S. GAAP net of any intercompany profits.

   11.5  Breach or Misrepresentation.  In the event of any material breach of 
this Agreement or any material misrepresentation of any representation or 
warranty contained herein by either party, the other party shall give the 
breaching party written notice thereof.  The breaching party shall have thirty 
(30) days after receipt of written notice to cure said breach.  If cure is not 
effected within the thirty (30) day period, the nonbreaching party shall have 
the right to terminate this Agreement.

12.  	NOTICES

    Except for COPLEY's Product orders which shall be sent to the address 
specified in Section 9 hereof, all notices which COPLEY gives HMRI shall be 
sent prepaid, either by first class mail, return receipt requested, express 
courier, telecopy, cable, or telex, addressed to HMRI as follows, unless 
otherwise notified in writing:

Hoechst Marion Roussel, Inc.
10236 Marion Park Drive
P.O. Box 9627
Kansas City, MO 64134-0627
Attn:  North America General Counsel
Telecopy:  (816) 966-3805


<PAGE 10>

    All notices which HMRI gives to COPLEY shall be sent in the same manner, 
addressed to COPLEY as follows, unless otherwise notified in writing:

Copley Pharmaceutical, Inc.
Canton Commerce Center
25 John Road
Canton, MA  02021
Attn:  President or Chief Financial Officer
Telecopy:  (617) 575-1856

    Any notice sent by mail shall be deemed given seventy-two (72) hours after 
the deposits thereof.  Any notice sent by express courier, telecopy, cable or 
telex shall be deemed given when actually received.

13.  	ASSIGNABILITY

    Neither party shall be entitled to assign its rights and obligations under 
this Agreement without the other party's prior written consent; provided, 
however, that (i) HMRI may assign its rights and obligations under this 
Agreement to any member of the Hoechst group companies engaged in the 
manufacture or sale of pharmaceutical products without the prior written 
consent of COPLEY or its assignee, and (ii) in the event of a sale of all or 
substantially all of the assets of COPLEY, COPLEY may assign its rights under 
this Agreement to the purchaser of such assets, provided such purchaser 
expressly assumes all of COPLEY's obligations under this Agreement, without 
the prior written consent of HMRI or its designee.

14.  	DISPUTE RESOLUTION

    Disputes between the parties will be settled by arbitration conducted 
under rules established by the American Arbitration Association.  The venue of 
such arbitration proceeding shall be in the state in which the party 
complained against resides.

15.  	SEVERING CLAUSE

    If any portion of this Agreement is held invalid by a court of competent 
jurisdiction, such portion shall be deemed to be of no force and effect and 
the Agreement shall be construed as if such portion had not been included 
herein.

16.  	ENTIRE AGREEMENT

    This Agreement contains the sole and entire understanding of the parties 
related to its subject matter and supersedes all prior or contemporaneous oral 
or written agreements concerning the subject matter.

17.	  MODIFICATION

    This Agreement cannot be changed orally and no modification of this 
Agreement shall be recognized nor have any effect, unless the writing in which 

<PAGE 11>

it is set forth is signed by HMRI and COPLEY, nor shall any waiver of any of 
the provisions of this Agreement be effective unless in writing and signed by 
the party to be charged therewith.

18.  	WAIVER

    The failure of either party to enforce, at any time, or for any period of 
time, the provisions hereof or the failure of either party to exercise any 
option herein shall not be construed as a waiver of such provision or option 
and shall in no way affect that party's right to enforce such provisions or 
exercise such option.  No waiver of any provision hereof shall be deemed a 
waiver of any succeeding breach of the same or any other provisions of this 
Agreement.

19.  	APPLICABLE LAW

    This Agreement shall be deemed to have been entered into within and shall 
be governed, construed and enforced in accordance with the laws of the State 
of Delaware, regardless of the choice of law principles of that or any other 
jurisdiction.

          IN WITNESS WHEREOF, the parties have caused this Agreement to be 
executed by the respective duly authorized officers on the dates and at the 
place indicated below:

COPLEY PHARMACEUTICAL, INC.                HOECHST MARION ROUSSEL, INC.


By:  /s/  Gene M. Bauer                    By:  /s/ Edward H. Stratemeier   
     --------------------------------           ----------------------------

Title: Executive Vice President and       Title: Vice President and 
         Secretary                                 General Counsel
       ------------------------------           ---------------------------- 





<PAGE 12>

                              SCHEDULE 1.1

                             MINIMUM QUANTITY


Strength                   Package Size                Minimum Quantity
--------                   ------------                -----------------

1.25 mg                      50 BTLS                        20,000

2.50 mg                     100 BTLS                        32,000
                            500 BTLS                         6,400
                            100 UD                          32,000


5.00 mg                     100 BTLS                        32,000
                            500 BTLS                         6,400
                           1000 BTLS                         3,200
                            100 UD                          32,000



<PAGE 13>

                                EXHIBIT A

                                   to

                          Amended and Restated
                           Glyburide Agreement
                                Between
                       Hoechst Marion Roussel, Inc.
                                 and
                       Copley Pharmaceutical, Inc.




                          1997 COST OF GOODS


During 1997, COPLEY's cost of goods for the Products from HMRI FOB 
Bridgewater, New Jersey (or such other U.S. location to which HMRI may move 
production of the Product) shall be based upon a bulk glyburide delivered cost 
to HMRI of [*] per kilo and shall be as follows:


		1000s     500s     100s     100sUD      50s
            -----     ----     ----     ------     ----
5.00 mg    $[*]      $[*]      $[*]      $[*]       ---

2.50 mg    $[*]      $[*]      $[*]      $[*]       ---

1.25 mg     ---        ---      ---       ---      $[*]








[*] Confidential portion has been omitted pursuant to a request for 
confidential treatment and has been filed separately with the Commission.




<PAGE 14>


                               EXHIBIT B

                                   to

                          Amended and Restated
                           Glyburide Agreement
                                Between
                       Hoechst Marion Roussel, Inc.
                                 and
                       Copley Pharmaceutical, Inc.




              CALCULATION OF HMRI REVENUE SHARE (Section 1.7)



COPLEY Gross Sales                                          $XXX

Less Actual:

					Chargebacks       $XXX
					Rebates           $XXX
					Price Adjustments $XXX
					Cash Discounts    $XXX

Net Sales                                            $XXX

Less Cost of Goods*                                         $XXX
                                                            ----

Net Profit Margin                                           $XXX

HMRI Net Profit Margin Share Percentage                     x [*]
                                                            ----

HMRI Net Profit Margin Share                                $XXX
                                                            ====



* Cost of Goods calculated on a fully allocated basis according to generally 
accepted accounting principles (as set forth in Section 1.5).



[*] Confidential portion has been omitted pursuant to a request for 
confidential treatment and has been filed separately with the Commission.


- 1 -